Tumor intrinsic factors related to immune evasion and ICI resistance
Overview of tumor intrinsic factors related to immune evasion and ICI resistance. (A) WNT/β-catenin signaling pathway: the loss of the adenomatous polyposis coli (APC) gene leads to increased β-catenin levels and activation of the WNT signaling pathway, which subsequently results in altered T-cell responses, a significant decrease in tumor-infiltrating lymphocytes, and tumor proliferation; (B) Interferon-γ (IFN-γ) signaling: IFN-γ facilitates tumor cell apoptosis and enhances the expression of the major histocompatibility complex class I (MHC-I) and programmed cell death ligand 1 (PD-L1) through the action of Janus Kinases (JAKs). The latter is essential for IFN-γ signaling, and mutations in JAK can lead to reduced tumor cell apoptosis in response to IFN-γ, the diminished expression of MHC-I, and T-cell exhaustion due to PD-L1 overexpression; (C) Antigen-presenting machinery (APM): (1) intra-tumor mechanisms such as mutations, loss of heterozygosis (LOS), or deletions in the β2M gene, as well as in the HLA-A, -B, and -C genes, trigger the loss of MHC-I. (2) Likewise, the improper assembling of β2M and alpha chains inside the endoplasmic reticulum lead to the unsuccessful expression of MHC-I. (3) In those situations, MHC-I-deficient tumor cells are not recognized by CD8+ T cells. (4) This results in an escape from immunological recognition. (5) This opens the way for proliferation and migration to different tissues; (D) Transforming growth factor beta (TGF-β): Mutations in either the TGF-β receptor or its downstream target, SMAD4, can result in a surge of TGF-β levels. Elevated levels of TGF-β could lead to the exhaustion of T cells and induce resistance to ICI treatment (created with BioRender.com).